AXON

Axon announced pricing of its $1.0 billion 0% convertible senior notes offering featuring capped calls to neutralize equity dilution.

Axon announced a proposed $1.0 billion offering of 0% convertible senior notes, triggering market fears of equity dilution.

The stock fell due to rising Treasury yields, executive insider selling, a Senate AI privacy inquiry, and post-earnings margin scrutiny.

The stock fell due to rising Treasury yields, post-earnings margin concerns, privacy scrutiny over AI tech, and an insider stock sale.

Axon surged following an Argus Research price target upgrade to $600 and a technical bounce off its 200-day moving average.

A spike in Treasury yields, Middle East tensions, margin fears, and insider selling caused a 16.54% decline in the stock.

A macro-driven surge in Treasury yields and rising U.S.-Iran geopolitical tensions sparked a sell-off in high-valuation growth stocks.

The stock dropped due to insider stock sales filings, high-multiple valuation compression, surging Treasury yields, and Middle East risks.

Axon stock surged following strong Q2 2026 results featuring 35.3% revenue growth, a 41% increase in bookings, and raised guidance.

Shares rallied due to institutional dip-buying after Q2 2026 earnings beat estimates and full-year revenue guidance was raised.

Axon surged following a Q2 2026 revenue and earnings beat alongside an upgraded full-year revenue growth guidance.

Axon fell after Q2 earnings showed software margin compression, rising component costs, and the withdrawal of cash flow guidance.

Shares surged due to heavy pre-earnings momentum buying and bullish analyst commentary ahead of the Q2 2026 earnings report.

The stock fell due to a broad tech selloff, profit-taking after a recent 30% surge, and executive insider trading disclosures.

The stock fell due to profit-taking following a 40% rally, CEO insider sale disclosures, and negative technical signals.

The stock dropped 12.10% due to profit-taking following a political rally, CEO insider selling, and technical mean-reversion.

Axon dropped due to profit-taking following a 40% rally, political scrutiny over an ICE contract, and a broad macro market sell-off.

Axon stock rallied on news of a Trump stock purchase linked to a $220M ICE contract notice and a Needham price target upgrade.

Axon stock surged following disclosures of a $220M federal contract pipeline, political news, and a Needham price target hike to $750.

The stock surged after reports revealed Donald Trump bought shares weeks before ICE solicited a $220 million contract for Axon weapons.

The stock surged following news of President Trump purchasing Axon stock shortly before ICE solicited a tailored $220M contract.

Disclosures showed President Trump bought AXON stock before ICE posted a $220M procurement notice matching TASER specifications.

AXON stock surged after disclosures revealed Donald Trump bought shares shortly before an ICE $220M contract notice was posted.